NICE prioritization board decisions published in August 2024

NICE recently introduced a new centralized approach to prioritizing topics for its guidance and a decision-making body - a prioritization board. In May 2024, a new NICE-wide topic prioritization manual was released, and a new specific webpage for topic prioritization was launched.

In August 2024, NICE prioritization board decisions were published regarding the following Med Tech-related topics:

• Lower urinary tract symptoms in men, trans and non-binary people with a prostate: assessment and management (clinical guidelines, update) – prioritized. The prioritization board agreed that this is a large population group where updated recommendations are likely to improve care;
• NPi-200 for pupillary light reflex in critical care patients (Medical Technologies Guidance) - not prioritized. The prioritization board agreed there was insufficient evidence in this area to develop useful guidance.
• Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia (Medical Technologies Guidance) - not prioritized. The prioritization board noted that there is an existing Interventional Procedures guidance on this topic (IPG770). That guidance can be considered for inclusion in the update of the guideline on lower urinary tract symptoms in men, trans and non-binary people with a prostate;
• Tumour treating fields for glioblastoma - not prioritized. The board agreed that this was an important area of clinical need. However, the evidence was limited, and based on the available evidence, the treatment was unlikely to be cost-effective. A commercial negotiation did not appear to be possible. The topic should be reconsidered once ongoing trials have been completed.

See the full details here and here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.